OptiBiotix Health (LSE:OPTI) is set to showcase its SweetBiotix sugar-substitute fibre technology at a shareholder sampling event scheduled to take place in London in June 2026.
The company said the presentation follows a manufacturing breakthrough that has improved production yields while also delivering a purer and better-tasting product with reduced ingredient and manufacturing costs. Existing shareholders and prospective investors have been invited to register online to attend the event.
Alongside product demonstrations, management plans to provide updates on the commercial development and market strategy for both its first- and second-generation microbiome-based product portfolio. The event forms part of OptiBiotix’s broader effort to accelerate commercialisation of its technologies while increasing engagement with investors and industry stakeholders.
By organising a dedicated SweetBiotix sampling session, the company aims to highlight the practical improvements made to its next-generation prebiotic sweetener platform and strengthen confidence in its commercial potential. OptiBiotix believes the SweetBiotix range could offer a health-focused alternative to traditional sugar products within the growing functional foods and nutrition market.
The company’s broader outlook remains pressured by ongoing losses and continued cash burn despite reporting strong revenue growth during 2024. Technical indicators also remain weak, reflecting a prolonged downward trend in the share price and negative market momentum.
However, OptiBiotix continues to benefit from a debt-free balance sheet, which provides some financial stability, although valuation remains difficult to support given the absence of profitability and dividend income.
More about OptiBiotix Health
OptiBiotix Health is a life sciences company focused on developing microbiome-based ingredients and products aimed at preventing and managing health conditions. Its portfolio includes brands such as SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators, alongside interests in skincare through SkinBioTherapeutics and probiotics via ProBiotix Health, targeting global consumer health and functional food markets.
Leave a Reply